A Phase 2 interventional study of Placebo and Enicepatide in Overweight or Obese and Type 2 Diabetes Mellitus (T2DM), sponsored by Carmot Therapeutics, Inc.. Completed at 70 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Carmot Therapeutics, Inc. · Phase 2, Interventional, and Treatment
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
3,670 studies on the registry are indexed under Overweight; 850 are open to participants now.
This study's enrollment of 447 is above the median of 73 across 3,175 interventional studies indexed under Overweight.
Browse Overweight studies →Carmot Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Placebo
Drug: Enicepatide
Drug: Enicepatide
Drug: Enicepatide
Drug: Enicepatide
Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Also known as: CT-388, RO7795068, RG6640
Percent Change in Body Weight from Baseline to Week 36
Time frame: Baseline to Week 36
Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36
Time frame: Baseline to Week 36
Percent Change in Body Weight from Baseline to Week 48
Time frame: Baseline to Week 48
Change in HbA1c from Baseline to Week 48
Time frame: Baseline to Week 48
Percentage of Participants with HbA1c <7.0% at Weeks 36 and 48
Time frame: Weeks 36 and 48
Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 36
Time frame: Baseline and Week 36
Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 48
Time frame: Baseline and Week 48
Percent Change in Body Weight from Baseline to Week 28
Time frame: Baseline and Week 28
Absolute Change in Body Weight (kg) from Baseline to Weeks 36 and 48
Time frame: Baseline to Weeks 36 and 48
Percent Change in Body Weight from Baseline to Weeks 16, 28, 36, and 48 by Obesity Class
Time frame: Baseline to Weeks 16, 28, 36, and 48
Change in HbA1c from Baseline to Weeks 16 and 28
Time frame: Baseline to Weeks 16 and 28
Change in HbA1c from Baseline to Weeks 16, 28, 36, and 48 by Obesity Class
Time frame: Baseline to Weeks 16, 28, 36, and 48
Percentage of Participants with HbA1c ≤6.5% at Weeks 16, 28, 36, and 48
Time frame: Weeks 16, 28, 36, and 48
Percentage of Participants with HbA1c <5.7% at Weeks 16, 28, 36, and 48
Time frame: Weeks 16, 28, 36, and 48
Change in 7-point Self-Monitored Blood Glucose (SMBG) Profile at Weeks 16, 28, 36, and 48
Time frame: Weeks 16, 28, 36, and 48
Percentage of Participants who Achieve HbA1c ≤6.5% and ≥10.0% Weight Reduction at Weeks 16, 28, 36, and 48
Time frame: Baseline, Weeks 16, 28, 36, and 48
Percentage of Participants who Achieve HbA1c <7.0% and ≥5.0% Weight Reduction at Weeks 16, 28, 36, and 48
Time frame: Baseline, Weeks 16, 28, 36, and 48
Change in Body Mass Index (BMI) from Baseline to Weeks 36 and 48
Time frame: Baseline, Weeks 36 and 48
Change in Waist Circumference from Baseline to Weeks 36 and 48
Time frame: Baseline, Weeks 36 and 48
Change in Hip Circumference from Baseline to Weeks 36 and 48
Time frame: Baseline, Weeks 36 and 48
Change in Waist-to-Hip Ratio from Baseline to Weeks 36 and 48
Time frame: Baseline, Weeks 36 and 48
Change in Waist-to-Height Ratio from Baseline to Weeks 36 and 48
Time frame: Baseline, Weeks 36 and 48
Change in Fasting Plasma Glucose from Baseline to Weeks 16, 28, 36, and 48
Time frame: Baseline to Weeks 16, 28, 36, and 48
Change in Fasting Insulin from Baseline to Weeks 16, 28, 36, and 48
Time frame: Baseline to Weeks 16, 28, 36, and 48
Change in Fasting C-peptide from Baseline to Weeks 16, 28, 36, and 48
Time frame: Baseline to Weeks 16, 28, 36, and 48
Change in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from Baseline to Weeks 16, 28, 36, and 48
Time frame: Baseline to Weeks 16, 28, 36, and 48
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carmot Therapeutics, Inc.